^
    1d
    A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Apr 2026 --> Dec 2027
    Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    Signatera™
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    2d
    Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K) (clinicaltrials.gov)
    P2, N=88, Not yet recruiting, Korea University Anam Hospital
    New P2 trial
    |
    Vectibix (panitumumab) • Fruzaqla (fruquintinib)
    7d
    Real-world pharmacovigilance and molecular mechanisms of fruquintinib: SRC and STAT3 as potential off-target mediators of proteinuria. (PubMed, Front Pharmacol)
    This clinical association might involve both classical vascular endothelial growth factor receptor blockade and the potential off target structural interactions of SRC and STAT3. These insights underscore the importance of early renal monitoring and offer structural insights into the drug's safety profile.
    Journal • Adverse events • Real-world evidence
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    Fruzaqla (fruquintinib)
    8d
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Huazhong University of Science and Technology
    New P2 trial
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    11d
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=404, Active, not recruiting, BeOne Medicines | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    14d
    A predictive model for treatment efficacy in RAS wild-type advanced colorectal cancer: development and external validation for EGFR inhibitor plus anti-angiogenic therapy based on a retrospective cohort. (PubMed, Sci Rep)
    This retrospective multi-center study included 600 RAS wild-type advanced CRC patients (development cohort: 420 patients from two centers; external validation cohort: 180 patients from an independent center) treated with EGFR inhibitors (cetuximab/panitumumab) plus anti-angiogenic agents (bevacizumab/fruquintinib/regorafenib) between 2018 and 2021. As a supplementary tool to current clinical guidelines, the model can partially address the problem of clinical response heterogeneity in combination therapy and provide simple decision support for clinicians in primary and secondary hospitals with limited detection conditions. However, the model has certain limitations in long-term prognostic prediction and needs to be further optimized and validated in larger, multi-center prospective cohorts before it can be translated into clinical practice of precision oncology.
    Retrospective data • Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab) • Stivarga (regorafenib) • Fruzaqla (fruquintinib)
    14d
    Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study (clinicaltrials.gov)
    P1/2, N=106, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P1/2 trial • Checkpoint inhibition
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    16d
    Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Sun Yat-sen University
    New P2 trial • IO biomarker
    |
    Fruzaqla (fruquintinib) • Hetronifly (serplulimab)
    19d
    A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs (clinicaltrials.gov)
    P3, N=142, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Stivarga (regorafenib) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • TQB2102
    19d
    Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial. (PubMed, ESMO Gastrointest Oncol)
    Patients with metastatic colorectal cancer (mCRC) who have progressed on fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic agents, and anti-epidermal growth factor receptor (EGFR) therapies have limited treatment options and poor prognosis, with a median overall survival (mOS) of ∼6 months on single-agent regorafenib or trifluridine/tipiracil. Tumor assessments occur every 8 weeks; follow-up continues for up to 18 months after enrolment. Optional translational research includes tumor, blood, and stool sampling to explore biomarkers of response and resistance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • RAS mutation
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Stivarga (regorafenib) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    23d
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=430, Enrolling by invitation, BeOne Medicines | Trial completion date: Dec 2026 --> Jul 2026 | Trial primary completion date: Dec 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    27d
    Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer. (PubMed, Front Oncol)
    It is anticipated that these findings will expand therapeutic options available to patients. https://www.chictr.org.cn/showproj.html?proj=140822, identifier ChiCTR 2200058323 (China Clinical Trial Center).
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)